(2R,3R)-2-(2,4-Difluorophenyl)-1-(1H-1,2,4-triazol-1-yl)butane-2,3-diol
97%
- Product Code: 113140
CAS:
133775-25-4
| Molecular Weight: | 269.25 g./mol | Molecular Formula: | C₁₂H₁₃F₂N₃O₂ |
|---|---|---|---|
| EC Number: | MDL Number: | ||
| Melting Point: | Boiling Point: | 485.0±55.0°C at 760 mmHg | |
| Density: | Storage Condition: | 2-8°C, store under inert gas |
Product Description:
This compound is primarily utilized in the pharmaceutical industry as an antifungal agent. It is particularly effective against a broad spectrum of fungal infections, including those caused by Candida and Aspergillus species. Its mechanism of action involves inhibiting the synthesis of ergosterol, an essential component of fungal cell membranes, thereby disrupting membrane integrity and leading to cell death. The compound is often formulated into oral tablets, topical creams, or intravenous solutions for the treatment of systemic and localized fungal infections. Its efficacy and safety profile make it a valuable option in both clinical and outpatient settings for managing fungal diseases.
Sizes / Availability / Pricing:
| Size (g) | Availability | Price | Quantity |
|---|---|---|---|
| 0.100 | 10-20 days | £7.12 |
+
-
|
| 0.250 | 10-20 days | £10.58 |
+
-
|
| 1.000 | 10-20 days | £26.46 |
+
-
|
| 5.000 | 10-20 days | £81.01 |
+
-
|
(2R,3R)-2-(2,4-Difluorophenyl)-1-(1H-1,2,4-triazol-1-yl)butane-2,3-diol
This compound is primarily utilized in the pharmaceutical industry as an antifungal agent. It is particularly effective against a broad spectrum of fungal infections, including those caused by Candida and Aspergillus species. Its mechanism of action involves inhibiting the synthesis of ergosterol, an essential component of fungal cell membranes, thereby disrupting membrane integrity and leading to cell death. The compound is often formulated into oral tablets, topical creams, or intravenous solutions for the treatment of systemic and localized fungal infections. Its efficacy and safety profile make it a valuable option in both clinical and outpatient settings for managing fungal diseases.
| Mechanism | - |
| Appearance | - |
| Longevity | - |
| Strength | - |
| Storage | - |
| Shelf Life | - |
| Allergen(s) | - |
| Dosage (Range) | - |
| Recommended Dosage | - |
| Dosage (Per Day) | - |
| Recommended Dosage (Per Day) | - |
| Mix Method | - |
| Heat Resistance | - |
| Stable in pH range | - |
| Solubility | - |
| Product Types | - |
| INCI | - |
Cart
No products
Subtotal:
£0.00
£0.00
Total :